Real-time Estimate
Cboe BZX
20:50:43 09/05/2024 BST
5-day change
1st Jan Change
20.68
USD
+2.78%
+1.61%
-25.43%
Presenter SpeechUnknown Analyst (Analysts)Good afternoon, everybody, and welcome to the 42nd A...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M
05-07
MT
Transcript : Veracyte, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07
Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024
05-07
CI
Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating
04-15
MT
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating
02-26
MT
Sector Update: Health Care Stocks Mixed Premarket Friday
02-23
MT
Needham Raises Price Target on Veracyte to $33 From $30, Maintains Buy Rating
02-23
MT
Veracyte's Q4 Loss Widens, Revenue Increases; Issues 2024 Revenue Outlook; Shares Down Pre-Bell
02-23
MT
Transcript : Veracyte, Inc., Q4 2023 Earnings Call, Feb 22, 2024
02-22
Earnings Flash (VCYT) VERACYTE Reports Q4 Revenue $98.2M, vs. Street Est of $92.8M
02-22
MT
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024
02-22
CI
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-22
CI
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-22
CI
Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors
02-13
CI
Veracyte Closes $70 Million C2i Genomics Acquisition
02-06
MT
Veracyte, Inc. completed the acquisition of C2i Genomics, Inc.
02-04
CI
Transcript : Veracyte, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01:30 PM
01-08
Veracyte, Inc. Provides Preliminary Unaudited Earnings Results for Fourth Quarter and Full Year Ended December 31, 2023
01-08
CI
Veracyte, Inc. has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.
01-07
CI
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday
12-04
MT
Veracyte Says New Data Backs Utility of Decipher Genomic Classifier to Treat, Manage Prostate Cancer
12-01
MT
Morgan Stanley Trims Price Target on Veracyte to $22 From $23, Maintains Underweight Rating
11-10
MT
Veracyte's Q3 Loss Widens, Revenue Increases; Raises 2023 Revenue Outlook
11-08
MT
Earnings Flash (VCYT) VERACYTE Reports Q3 Revenue $90.1M, vs. Street Est of $84.4M
11-07
MT
Transcript : Veracyte, Inc., Q3 2023 Earnings Call, Nov 07, 2023
11-07
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
More about the company
Last Close Price
20.12
USD
Average target price
29.83
USD
Spread / Average Target
+48.28%
Consensus
1st Jan change
Capi.
-25.43% 1.54B -25.69% 10.94B +66.11% 3.75B -28.39% 2.27B -10.06% 2.25B +52.14% 1.18B -2.84% 754M -8.50% 529M -28.27% 469M +14.12% 340M
Bio Diagnostics & Testing
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1